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Abstract
Background: Three tesla (3T) coronary magnetic resonance angiography (MRA) may be optimized using
gadolinium-based contrast agents (GBCA) such as gadofosveset trisodium. The goal of this study was to evaluate if
there is a qualitative or quantitative improvement in the coronary arteries with variation in contrast dose.
Methods: Twenty-eight healthy volunteers were prospectively recruited for coronary MRA at 3T using a steady
state injection technique for 3D radial whole-heart image acquisition with retrospective respiratory self-gating
(ClinicalTrials.gov identifier: NCT01853592). Nineteen volunteers completed both single- and double-dose imaging
instances (0.03 and 0.06 mmol/kg, respectively). Intra-individual comparison of image quality was assessed by
measurement of apparent signal/contrast-to-noise ratio (aSNR/aCNR) and subjective evaluation of image quality
by 2 independent reviewers.
Results: The average duration of coronary MRA acquisition was 7.2 ± 1.2 min. There was significantly higher
(60 %, p < 0.001) aSNR of the aorta and right/left ventricle for the double dose compared to single dose injection scheme
and aSNR of the coronary arteries increased by 70 % (p < 0.001) for the double dose injection. aCNR increased by +55 %
and +60 % in the ventricles and coronary arteries, respectively (p < 0.001). Overall segmental artery visualization for single
dose was possible 47 % of the time, which improved to 60 % with double dose (p = 0.019), predominantly driven
by improvements in more distal segment visualization (+40 % improvement in mid arterial segments, p = 0.013).
Conclusions: Gadofosveset trisodium dose of 0.06 mmol/kg significantly quantitatively and qualitatively improves
the coronary artery image quality compared to 0.03 mmol/kg at 3T for moderate duration (6–8 min) steady state
contrast enhanced coronary MRA.
Keywords: Gadofosveset trisodium, MS-325, Gadolinium-based intravascular contrast agent, Whole-heart coronary
magnetic resonance angiography, Navigator-based angiography, 3.0 Tesla, Image quality, Respiratory motion correction
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Background
Coronary artery disease (CAD) remains a leading cause
of morbidity and mortality in the world. CT coronary
angiography (CCTA) is the reference standard for non-
invasive cross-sectional imaging of the coronary arteries.
Coronary MRA can often be combined with venography,
and comprehensive evaluation of myocardial function
and structure. In addition, concerns regarding iodinated
contrast allergy or concerns about ionizing radiation
make coronary MRA appealing [1, 2]. However,
coronary MRA remains technology challenging, espe-
cially at 3 Tesla compared to CCTA [3]. Therefore,
further optimization is needed.
In general, coronary MRA has long scan times (5–15
min) because high resolution, wide spatial coverage and
prospective respiratory gating via a diaphragmatic naviga-
tor has been required. Steady state free precession (SSFP)
imaging is effective at defining coronary anatomy at 1.5T
[4]. However at 3T, B0 and B1 field inhomogeneity and
specific absorption rate (SAR) considerations result in lim-
itations for a noncontrast approach. Contrast enhanced
whole-heart imaging utilizing an inversion recovery tech-
nique is an alternative [5]. Long scan duration precludes
the use of extracellular GBCAs, which have very short
intravascular residence times (less than 1 min). An alter-
native approach uses an intravascular contrast agent such
as gadofosveset trisodium (Ablavar®, Lantheus Medical
Imaging, North Billerica, MA, USA). Gadofosveset has a
high affinity for albumin, which resides predominately in
the intravascular compartment, thus resulting in much
longer enhancement of blood vessels compared to con-
ventional extravascular MRI contrast agents (~10 min vs.
30 s, respectively) [6]. Gadofosveset has been validated at
1.5T for angiography of aortoiliac atherosclerotic disease
using a dose of 0.03 mmol/kg [4, 7]. However, unlike the
relatively motion-free aorta and iliac arteries, coronary
MRA is complicated by the need to account for cardiac
and coronary artery motion. Thus, the optimal dose of
gadofosveset for coronary MRA at 3T had not been deter-
mined. For peripheral MRA, so-called “double-doses” of
conventional GBCAs have shown to significantly increase
raw signal intensity, SNR, and CNR [8, 9]. Double dosing
is also commonly applied to cardiac MRA [10].
Advances in coronary whole-heart MRA acquisition
with 100 % gating efficiency reduces acquisition time for
coronary MRA by a factor of 2.5 to 3 or more [11, 12].
Thus, a coronary MRA duration of less than 10 min
mimics our initial development of peripheral contrast
enhanced MRA that was optimized for this timing with
gadofosveset, intended for use in “double dose” gadolin-
ium injection schemes [13].
The primary purpose of this study was to determine if
the diagnostic quality and image characteristics of contrast-
enhanced coronary magnetic resonance angiography
(MRA) at 3T is improved by using a higher dose of gado-
fosveset combined with 100 % efficient whole heart coron-
ary MRA. A secondary goal was to assess the patient




Following approval by the National Heart, Lung, and
Blood Institute institutional review board at the National
Institutes of Health (NCT01853592), 28 subjects were
recruited with written informed consent. Subjects were
included between the ages of 18–45. Exclusion criteria
contained standard MRI safety criteria, pregnancy,
GBCA administration within 30 days, history of severe
asthma, diagnosis of CAD, liver or kidney failure, and
history of arrhythmia. After a focused history and phys-
ical exam, serum human chorionic gonadotropin and
creatinine were drawn to exclude pregnancy or kidney
failure, respectively. A complete blood count was drawn
to screen for blood dyscrasia or other hematologic ab-
normality. Immediately prior to imaging, weight, height,
heart rate, and blood pressure were recorded.
MR angiography
Standard gadofosveset dosing followed the package in-
sert for a single dose of 0.12 mL/kg (0.03 mmol/kg),
whereas the double dose protocol used 0.24 mL/kg
(0.06 mmol/kg). Using a previously validated dual-
injection technique specific to gadofosveset [13], the dose
was diluted to 50 mL with normal saline. A more rapid in-
jection (1.5 mL/sec) phase was immediately followed by a
continuous slow infusion (0.04 mL/sec), designed to main-
tain steady-state intravascular concentration. The rapid/
slow infusion volume ratio was 60 %/40 %. All exams used
a single Spectris Solaris EP (MEDRAD Inc., Pittsburgh,
PA, USA) GBCA injector. Subjects underwent the double
dose protocol, a 30-day waiting period, and the single dose
protocol. If heart rate was greater than 70 beats per min
prior to imaging, patients received up to 100 mg oral
metoprolol tartrate (Mylan Pharmaceuticals, Canonsburg,
Pennsylvania, USA).
MR data was collected using a 3T MAGNETOM
Verio (Siemens Medical Solutions, Erlangen, Germany)
with a 32 channel receiver coil array using a contrast-
enhanced, free-breathing, electrocardiogram (ECG)-
gated, fat-saturated and inversion-recovery prepared
spoiled gradient echo sequence with the following pa-
rameters: TE/TR = 3.5/1.8 ms, inversion time = 350 ms,
bandwidth = 704 Hz/pixel, field of view = 4003 mm3,
matrix size = 3843, 3D radial k-space trajectory, number
of projections = 12,000. The trigger delay and acquisi-
tion window length in ECG gating were set according to
the mid-diastolic quiescent period. No prospective
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respiratory gating was performed. Rather, respiratory
motion-corrected reconstruction was performed retro-
spectively offline using a previously validated method,
whereby the raw MR data was binned into respiratory
phases based on the self-navigation projections, and the
respiratory motion was corrected using an image-based
registration approach [11, 12].
Immediately following imaging, the subjects were
asked open-ended questioning regarding any uncomfort-
able side effects due to contrast infusion, which were
subjectively graded by the participant on a scale of 0
(none) to 10 (severe).
Image processing and analysis
Using Osirix™ version 5.8.5 (Pixmeo SARL, Geneva,
Switzerland), the aSNR and aCNR were calculated in
reference to the myocardium by drawing large regions of
interest (ROI) in the left ventricle (242 ± 64 mm2), right
ventricle (184 ± 62 mm2), descending aorta (75 ± 22 mm2),
and ascending aorta (163 ± 65 mm2). Likewise, a smaller
ROI was drawn for the coronary left main (LM) artery in
the same plane that it branched from the ascending aorta
(6 ± 2 mm2). However, as the spatial resolution limited ac-
curate ROIs being drawn for coronary arterial lumen,
aSNR and aCNR values were obtained by averaging indi-
vidual pixel densities of three pixels within the proximal ar-
terial lumen (pixel size = 1.04 mm2) for the right coronary
artery (RCA), left anterior descending (LAD), and left cir-
cumflex (LCX) coronary arteries. For the reference myo-
cardium, three separate ROIs were drawn over the septum
(each 12 ± 1.4mm2) in the two-chamber view and signal
intensities were averaged. Similarly, background air inten-
sity was calculated using a large ROI superior to the chest
cavity (25.5 ± 11.4 cm2). The equations used to calculate
aSNR and aCNR (relative to myocardium) were then used






Two cardiologists experienced in coronary imaging
(FZ, VS) performed blinded independent review of the
coronary arteries for diagnostic quality in the LAD, LCX,
and RCA in the proximal and mid portions of the artery.
To measure overall difference in quality between dosing
attempts, image quality was reported using a qualitative
scale of 0 (artery segment not visualized), and 1 (visualized).
For measurements of inter- and intra-reader agreement, a
more gradated categorical scale was used: 0, not interpret-
able; 1, poor (severe artifacts); 2, good (mild to moderate
artifacts); 3, very good (minimum to mild artifacts); 4, ex-
cellent (minimum or no artifacts).
Using a higher (0.05 mmol/kg) dose of Gadofosveset,
prior studies have observed an approximately 50 % in-
crease in CNR and 40 % increase in SNR in the periph-
eral and central vasculature compared to the standard
0.03 mmol/kg dosing scheme [14]. In a similar fashion,
we separately evaluated aCNR and aSNR for gadofosveset
coronary angiography [15]. Using this a priori information,
we determined sample size for a paired comparison with
beta = 0.8 and alpha = 0.05 to detect a 50 % increase in
aCNR, and 40 % increase in aSNR for 0.06 mmol/kg com-
pared to 0.03 mmol/kg gadofosveset. 19 subjects provided
at least 80 % power; additional subjects were recruited to
account for potential subject withdrawal prior to comple-
tion of two MRI scans.
Significant differences in quantitative and qualitative
image quality parameters were calculated using Wilcoxon
matched-pairs signed rank test. The intra- and inter-class
correlation coefficient (ICC) was calculated for per-
segment qualitative scores for single readers and between
readers. Chi square analysis was performed for the deter-
mination if there was a higher proportion and severity of
side effects due to double dosing among subjects who
completed both single and double dose instances. Statis-
tical significance was considered to have a p-value < 0.05.
Differences in demographic, physiologic, and lab parame-
ters between single dose and double dose scanning were




With demographics shown in Table 1, 22 of 28 subjects
recruited were able to complete the initial double-dose
imaging, of which, 19 completed the follow up single-
dose imaging. A total of 9 subjects met exclusion criteria
during the protocol because of: pre-screening lab values
out of the normal range (4 subjects), lack of adequate
intravenous access (1 subject), self-withdrawal prior to
imaging (1 subject), or loss to follow-up following the
initial MRI (3 subjects).
MRA imaging time for double and single dose in-
stances was not significantly different, with an overall
average of 7.2 ± 1.2 min.
Quantitative evaluation
Shown in Table 2, there were uniform, statistically signifi-
cant increases in aSNR for all regions measured. aCNR
also increased for all segments with the exception of the
LCX (p = 0.09). Overall, there was an approximate 60 %
increase in aSNR of the aorta and ventricles (p < 0.001)
and an approximate 70 % increase (p < 0.001) in the cor-
onary arteries. There was a similar increase in aCNR of
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the aorta/ventricles and coronary arteries, representing
approximately +55 % (p < 0.001) and +60 % (p < 0.001),
respectively.
Qualitative evaluation
Shown in Table 3, there were statistically significant im-
provements in qualitative vessel measurements with
double dosing. Improvement was evidenced primarily in
the mid portions of the artery (+40.6 %, p = 0.013). Al-
though there was a uniform trend for an increase in ves-
sel identification for all segments measured, statistically
significant changes were not shown for the proximal
LCX and proximal and distal RCA. With all proximal
and mid segments included for evaluation, the overall
vessel identification at single dose was 0.47 ± 0.27, which
improved to 0.60 ± 0.25. The intra-and inter-class cor-
relation coefficients were high for proximal coronary ar-
tery segments (ICC >0.7), with mixed results in the mid
to distal segments.
Images representative of a perceptible visual difference
in image quality between the single and double dosing
protocol is shown in Fig. 1. Curved multiplanar recon-
struction and 3-dimensional volume surface reconstruc-
tion of the heart using the double dose protocol are
shown in Figs. 2 and 3, respectively.
Side effect severity
Following the initial double dose injection, one subject
was excluded from further study because of the feeling
of self-limiting “throat tightening” and throat pruritus. A
second subject did not return for single dose scanning
for undisclosed reasons. Of patients completing both ex-
aminations, more patients reported side effects of at
least 1 out of 10 severity for double dose compared to
single dose injection (65 % vs 42 %, p < 0.0001).
Symptom severity was also higher (p < 0.0001) in double
dose compared to single dose injection with a mean of






Age 29.6 ± 6.8 29.1 ± 6.7 NS
Male 26.3 % (5/19) 22.7 % (5/22) NS
Height (cm) 165.4 ± 7.5 165.9 ± 7.3 NS
Weight (kg) 71.6 ± 20.2 70.9 ± 19.2 NS
Body mass index
(kg/m2)
26.0 ± 6.2 25.6 ± 5.9 NS
Hematocrit (%) 41.1 ± 5.6 40.7 ± 6.1 NS
Creatine (mg/dL) 0.81 ± 0.16 0.80 ± 0.15 NS
eGFR (mL/min/1.73 m2) 113.0 ± 11.6 107.8 ± 12.1 NS
Heart rate (bpm) 66.7 ± 7.0 66.1 ± 11.0 NS
Systolic blood pressure
(mmHg)
117.6 ± 11.5 117.1 ± 12.1 NS
Diastolic blood pressure
(mmHg)
72.3 ± 9.9 70.1 ± 10.6 NS
Imaging Parameters
Dose (mL) 8.6 ± 2.4 17.1 ± 4.7 <0.001
Imaging time (min) 6.8 ± 1.2 7.5 ± 1.2 NS
NS Non significant
Table 2 Quantitative aSNR and aCNR evaluation
aSNR aCNR
Level Single dose Double dose P value Single dose Double dose P value
Left Ventricle 11.0 ± 4.5 17.3 ± 7.8 <0.001 6.0 ± 2.7 9.0 ± 5.0 0.002
Right Ventricle 10.7 ± 8.4 16.7 ± 11.7 <0.001 5.7 ± 6.8 8.4 ± 9.2 0.006
Desc. Aorta 9.5 ± 4.0 15.6 ± 8.1 <0.001 4.5 ± 2.9 7.2 ± 5.5 0.01
Prox. Aorta 13.1 ± 6.1 21.9 ± 10.6 <0.001 8.1 ± 4.5 13.6 ± 7.7 <0.001
Overall 11.1 ± 6.0 17.9 ± 9.8 <0.001 6.1 ± 4.6 9.5 ± 7.3 <0.001
LMS 10.5 ± 4.8 18.2 ± 8.1 <0.001 5.4 ± 3.6 9.6 ± 6.4 0.002
LAD 14.5 ± 4.3 23.6 ± 8.7 <0.001 9.0 ± 3.7 14.1 ± 8.3 0.02
LCX 10.7 ± 3.5 16.5 ± 4.3 <0.001 5.5 ± 3.1 7.8 ± 4.5 0.09
RCA 15.5 ± 6.6 25.3 ± 11.0 <0.001 10.4 ± 5.1 16.7 ± 10.0 0.01
Overall 12.8 ± 5.4 21.0 ± 9.1 <0.001 7.6 ± 4.5 12.1 ± 8.3 <0.001
Other
Myocardium 4.9 ± 2.3 8.3 ± 3.8 <0.001
There is higher aSNR and aCNR with double dose gadofosveset
aSNR Apparent signal-to-noise ratio
aCNR Apparent Contrast-to-noise ratio (relative to the myocardium)
LM Left main coronary artery
LAD Left anterior descending coronary artery
LCX Left circumflex coronary artery
RCA Right coronary artery
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Table 3 Qualitative evaluation
Mean image quality Wilcoxon ICC
Level Single dose Double dose Δ % P value Intra Inter
LADprox 0.65 ± 0.40 0.89 ± 0.26 36.9 0.004 0.77 0.81
LADmid 0.48 ± 0.33 0.60 ± 0.29 25.0 0.048 0.44 0.7
LCXprox 0.52 ± 0.39 0.62 ± 0.40 19.2 NS 0.73 0.76
LCXmid 0.14 ± 0.25 0.33 ± 0.35 135.7 0.020 0.6 0.51
RCAprox 0.68 ± 0.38 0.69 ± 0.40 1.5 NS 0.87 0.79
RCAmid 0.33 ± 0.24 0.43 ± 0.38 30.3 NS 0.48 0.61
Overallprox 0.62 ± 0.36 0.73 ± 0.29 17.7 NS - -
Overallmid 0.32 ± 0.22 0.45 ± 0.27 40.6 0.013 - -
Overallprox+mid 0.47 ± 0.29 0.60 ± 0.25 27.7 0.019 - -
Double dosing results in higher per-segment image quality of arterial segments. Statistically significant changes are shown in bold
LAD Left anterior descending coronary artery
LCX Left circumflex coronary artery
RCA Right coronary artery
prox Proximal
mid Middle
Fig. 1 Visual comparison of image quality with double dose. Double dose (left column) and single dose (right column) maximum intensity
projection MRA images of the heart for two subjects (top and bottom rows). Visually compared to single dose images (b and d), double dose
images (a and c) show appreciably higher image quality of the LAD (white arrow), RCA (white arrowhead), and LCX arteries (black arrow).
Window and level is fixed for representative image comparisons per subject
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2.83 ± 2.61 and 1.13 ± 1.80, respectively. Ranked in
order of occurrence, the most common reported side ef-
fects are shown in Table 4.
Discussion
At 3.0-Tesla field strength, contrast-enhancement of the
coronary arteries has been explored for MRA [5] and
gadofosveset has shown promise in this application [16].
Previous use of gadofosveset in coronary MRA has
shown a small increase in image quality compared to the
more conventional MR contrast agents [15]. Further-
more, the long intravascular residence time and high T1
relaxivity may afford improvements in self-navigated
respiratory motion compensation [17]. This strategy with
gadofosveset is desirable for the 3D radial protocol used
in this study as each k-space line contributes equally to
the image contrast; therefore a stable contrast enhance-
ment throughout the scan duration is desired. Add-
itional diagnostic improvements with higher doses of
gadofosveset have not been systematically evaluated with
these advanced reconstruction techniques. Our results
found higher aSNR and aCNR, as well as superior image
quality represented by higher qualitative yield, particu-
larly in the mid arterial segments. Our finding of signifi-
cant increases in the more distal segments may be
expected because of the opportunity to increase the
Fig. 2 Curved multiplanar reconstruction of the LAD (white arrowheads)
using an image acquired with the double dose steady state injection
protocol. The LAD can be followed from the proximal (right) to the
distal segment (left), and is seen wrapping around the apex of the left
ventricle (far left)
Fig. 3 Example of a 3-dimensional projection of a coronary angiogram
using a double dose injection protocol. The LAD can be followed to its
most distal segment, wrapping around the apex of the heart
Table 4 Side effect profile




12 Pelvic tingling Probable Yes




5 nausea Probable Yes
3 Nasal congestion Unlikely No
2 Metallic taste Probable Yes
2 Saline smell Probable Yes
2 Increased salivation Probable Yes
2 Warm sody sensation Probable Yes
1 Pelvic pressure Probable Yes
1 Pelvic discomfort Probable Yes
1 Low back pain Unlikely No
1 Prickly sensation Probable Yes
1 Cold body sensation Probable Yes
1 Tingling body sensation Probable Yes
1 Reflux sensation Unlikely No
1 Throat itching Probable Yes
1 Throat irritation Probable Yes
More than one symptom could be reported by a single participant
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otherwise poor luminal signal intensity at these levels be-
cause of small vessel caliber, compared to the proximal
segments where single dose may suffice for visualization
of the larger caliber artery at this level. Nonetheless, our
results did show a statistically significant qualitative im-
provement in the proximal LAD. Despite a uniform trend
for improved aCNR, aSNR, and qualitative measurement
with double dose across all vascular territories, statistical
significance was lacking in qualitative measurement in the
LCx and RCA territory and with aCNR of the LCX, which
may be due to limitations in field homogeneity, higher re-
gional respiratory or cardiac motion, or limitations in
sample size. With the intent for a robust evaluation of the
entire coronary arterial tree with MR, there is promise in
the combination of a higher dosing of gadofosveset along
with other improvements in image acquisition [18].
Regarding the technique of coronary MRA with gado-
fosveset, we were able to target the image acquisition for
the mid-diastolic quiescent period prior to contrast in-
jection. Anecdotally, we observed an increase in the
heart rate just after injection (5–15 beats per minute in-
crease), which may have altered the mid-diastolic rest
phase timing relative to the pre-planning cine images. In
this regard, further improvements in image quality may
follow with real-time adaptation to heart rate changes or
other methods to mitigate the effect of heart rate vari-
ability [19], in addition to stabilization of heart rate with
beta blockade [20].
Double dose injection protocols appear to predomin-
ate in current practice for cardiac MRI [10]. Increased
risk of nephrogenic systemic sclerosis (NSF) as well as
patient comfort are factors to consider for dose increases
of gadolinium-based contrast agents [21]. We did not
evaluate the long term safety of our dosing scheme, al-
though gadofosveset safety of 0.03, 0.05, and 0.07 mmol/kg
dosing has been previously reported [7]. Although patients
reported an increase in the side effects of the higher dose
of gadofosveset in this study, we did not observe severe
contrast reactions for either dosing scheme. Because any
abnormal liver or kidney function measurement resulted
in exclusion from participation, the safety of higher doses
of gadofosveset for patients with health complications is
not evaluated here.
Conclusions
The use of double doses of gadofosveset trisodium re-
sults in higher qualitative and quantitative image quality
compared to the standard single dose. In combination
with further improvements in technique, double dosing
shows promise for use in coronary MR angiography at
3.0 Tesla. Diagnostic efficacy could be further evaluated
to determine whether the superior image quality allows
better assessment of coronary structural abnormalities in
atherosclerotic patients.
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